articleThe Lancet OncologyJun 5, 2016BRONZE OA

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

SAScott AntoniaJAJosé A. López-MartínJCJohanna C. BendellPAPatrick A. OttMHMatthew H. Taylor

Moffitt Cancer Center · Hospital Universitario 12 De Octubre · +29 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,252
total citations
FWCI
75.62
Percentile
100%
References
32
Citations per year

Authors

24

Topics & keywords

Topics
Keywords
  • Nivolumab
  • Ipilimumab
  • Medicine
  • Tolerability
  • Internal medicine
  • Regimen
  • Lung cancer
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding